Left atrial to ventricular volume ratio is a specific marker of atrial cardiopathy.

Evidence from the UK Biobank and an ischemic stroke patient cohort.

Julian Deseoe[1], Martin Hänsel, MD[1], Lisa Herzog, PhD[1], Neda Davoudi, PhD[2,3], Andreas R. Luft, MD[1,4], Catherine Gebhard, PhD[5], Bjoern Menze, PhD[3], Beate Sick, PhD[6], Susanne Wegener, MD[1*]

[1]Department of Neurology and Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Switzerland

[2]ETH Zurich, Institute for Biomedical Engineering, Department of Information Technology and Electrical Engineering, Zurich, Switzerland

[3]Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland

[4]cereneo Center for Neurology and Rehabilitation, Vitznau, Switzerland

[5]Department of Cardiology, Inselspital University Hospital Bern, University of Bern, Bern Switzerland

[6]Epidemiology, Biostatistics & Prevention Institute, University of Zürich, Zürich, Switzerland

Short title: LA:LV ratio is a marker for atrial cardiopathy

***Corresponding Author:**

Susanne Wegener

Department of Neurology

University Hospital Zurich

Frauenklinikstrasse 26

8091 Zurich, Switzerland

Phone: +41 44 255 1111

Email: Susanne.wegener@usz.ch

Abstract

Background: Atrial cardiopathy is an important cause of embolic stroke. Increased left atrial volume indexed to body surface area (LAVi) has been widely used as marker for atrial cardiopathy. However, since physiological remodeling may also increase LAVi, it lacks specificity. Left atrial to left ventricular volume (LA:LV) ratio was recently suggested as a better marker of atrial cardiopathy allowing a more accurate detection of imbalanced, pathological atrial remodeling. We investigated if LA:LV ratio is associated with different established sequelae of atrial cardiopathy and if it is superior to LAVi for the detection of atrial fibrillation/flutter (AF) as cause of stroke.

Methods: We compared the association of LAVi and LA:LV ratio with risk of ischemic stroke or transient ischemic attack (TIA) in the UK Biobank cohort (n= 38'848), using cause specific hazard models. In addition, we assessed association with cognitive function using multivariate linear regression models. Finally, we investigated the association of LAVi and LA:LV ratio with probability of atrial fibrillation/flutter being identified as stroke etiology in a cohort of ischemic stroke patients (n = 1'273). We compared the test performance of LAVi and LA:LV ratio for identifying atrial fibrillation/flutter as stroke etiology.

Results. While LAVi was not significantly associated with risk of ischemic stroke/TIA (HR: 1.11, 95% CI 0.97 - 1.26, p = 0.14), a larger LA:LV ratio was (HR: 1.15, 95% CI 1.01-1.30, p = 0.04). Besides, LA:LV ratio was more strongly associated with worse cognitive function in healthy adults [LA:LV ratio: -0.024 (95% CI (- 0.032) - (- 0.015)), LAVi: - 0.010 (95% CI (- 0.019) - (- 0.002))]. In a stroke patient cohort, LA:LV ratio showed a significantly better performance in identifying AF as underlying cause of ischemic stroke compared to LAVi (Receiver Operating Characteristic Area under the Curve 0.856 (0.803- 0.908) vs. 0.808 (0.750 - 0.866) p = 0.03).

Conclusions. We provide evidence that LA:LV ratio is a superior marker for atrial cardiopathy compared to LAVi. Hence, LA:LV ratio has the potential to improve diagnosis of atrial cardiopathy, facilitating prophylaxis of ischemic stroke.

1. Introduction

Atrial cardiopathy is a structural and functional disorder of the atria. In atrial cardiopathy, different mechanisms including oxidative stress and inflammation lead to structural, contractile and electrophysiological changes of the atria [1]. This has been associated with higher risk of stroke [2] and lower cognitive performance [3]. The leading explanatory hypothesis is that due to remodeling in atrial cardiopathy, thrombogenicity of the atria increases. [4] Similarly, in patients with atrial cardiopathy, cerebral micro-embolism due to increased atrial thrombogenicity may lead to cognitive decline even in the absence of ischemic stroke [3, 5, 6]. Atrial cardiopathy has been also linked to cortical atrophy [3]. There is increasing evidence that anticoagulation may reduce future cardiovascular events in patients with atrial cardiopathy, even in the absence of atrial fibrillation or flutter (AF) [7]. However, the diagnosis of atrial cardiopathy in the absence of AF is not yet reliable enough to justify anticoagulation.

Although the importance of atrial cardiopathy is increasingly apparent, reliable methods for its diagnosis are still sparse [4]. Large left atrial volume indexed to body surface area (LAVi) has been commonly used as an indicator of atrial cardiopathy [8]. Increased LAVi has been associated with increased risk of ischemic stroke [9-11] and poorer cognitive function [3, 12, 13], although there has been some variation between studies. In clinical practice, increased LAVi can indicate ischemic stroke patients with high likelihood of AF as underlying stroke cause [14].

However, the use of LAVi for the detection of atrial cardiopathy has important limitations. Physiological remodeling of the left atrium, for example due to increased physical activity, can also lead to increased LAVi [15]. Thus, better cardiorespiratory fitness has been associated with larger LAVi, complicating the use of this parameter as a marker of pathological remodeling [16]. Recently, the left atrial to ventricular volume (LA:LV) ratio,

defined as the ratio between the maximal left atrial volume at end systole and left ventricular end diastolic volume (LVEDV) has been proposed as a marker to better differentiate between balanced, physiological and imbalanced, pathological left atrial enlargement [17, 18]. This is based on the observation that physiological remodeling, such as that induced by exercise, typically results in proportional increases in both left atrial volume and left ventricular volume, thereby maintaining a relatively stable LA:LV ratio. [15]. However, associations of LA:LV ratio with known sequelae of atrial cardiopathy have never been systematically studied.

In this context, we aimed to compare the LA:LV ratio and the LAVi as indicators of atrial cardiopathy, by investigating their associations with different known sequelae of atrial cardiopathy. First, we evaluated the associations of LAVi and LA:LV ratio with the risk of ischemic stroke or transient ischemic attack (TIA) in a subpopulation of the UK Biobank cohort. Second, we assessed their associations of LAVi and LA:LV ratio with cognitive function and cortical atrophy in a subpopulation of the UK Biobank cohort. Finally, we examined the predictive performance of LAVi and LA:LV ratio for identifying AF as the underlying cause of stroke in a cohort of ischemic stroke patients from the University Hospital Zurich (USZ).

2. Methods

In this study, we analyzed data from two distinct cohorts. First, we analyzed data from the large, population-based UK Biobank cohort to explore associations in the generally healthy population. We then investigated the clinical relevance of these findings from the UK Biobank in a cohort of ischemic stroke patients from the University Hospital Zurich (USZ).

2.1 Investigating association between cardiac volumes and risk of ischemic stroke/TIA as well as cognitive function in the UK Biobank

2.1.1 Cohort Description

The UK Biobank is a large prospective cohort study, which holds data of around half a million (n = 502'128) participants from the UK. The recruitment protocol is publicly available [19]. The UK Biobank imaging study contains among other assessments, cardiac magnetic resonance (CMR) imaging for over 50’000 participants. We worked with the data release from March 2025 (v19).

2.1.2 Cardiac magnetic resonance imaging and cardiac volumes

UK Biobank CMR imaging is performed using 1.5 T scanners (MAGNETOM Aera, Syngo Platform VD13A, Siemens Healthcare, Erlangen, Germany) according to a standardized protocol. [20]. We worked with data from the first imaging visit. From these images standard cardiac metrics including maximum left atrial volume, LVEDV and left ventricular ejection fraction (EF) have already been extracted using deep learning techniques described elsewhere [21]. Based on these measurements, LA:LV ratio was calculated by taking the ratio of LA maximum volume at end systole and LVEDV. Left atrial maximum volume at end systole was divided by body surface area (BSA) to obtain LAVi as has been done in previous studies and in clinical practice. [22]. The LAVi and LA:LV ratio were then standardized to have a mean of zero and a standard deviation of one to facilitate comparison of effect sizes.

2.1.3 Participant selection

2.1.3.1 Cardiac volumes and risk of ischemic stroke/TIA in the UK Biobank

Data of all participants with available information on LA volume were considered for analysis. For assessment of stroke risk, patients with AF diagnosed before the imaging date, as well as patients with reduced EF or left ventricular dilation were excluded.

Participants with AF were excluded as quantification of cardiac volumes in these patients can be imprecise [23] and as AF itself is known to be associated with risk of ischemic stroke. We decided to exclude patients with heart failure, reduced ejection fraction and LV dilation, as the interplay between left atrial volume and left ventricular volume changes in these patients [24]. Hence, these likely warrant a separate investigation. In addition, participants with prior stroke or TIA were excluded for analysis concerning risk of stroke/TIA. All participants with incomplete data were excluded. Details of how participants with AF, heart failure LV dilation and reduced EF were identified can be found in the supplemental methods.

2.1.3.2 Cardiac volumes and cognitive function

The same inclusion and exclusion criteria were applied with two exceptions. Patients with prior TIA were not excluded while those with preexisting dementia were excluded. An overview of inclusion and exclusion of participants can be found in Figure 1.

2.1.4 Ascertainment of covariates

We adjusted our models for the covariates shown in Table 2. Compared to models for associations with stroke/TIA risk, models on cognitive function were additionally adjusted for whether participants had reported having a university degree or not. Details on how the covariates were defined can be found in the supplemental methods and Table S1.

2.1.5 Calculating survival times for ischemic stroke/TIA risk analysis

A composite outcome was defined using the earliest occurrence of "Date of ischemic stroke" and "Date first reported transient cerebral ischemic attacks and related syndromes" to indicate the event date of brain ischemia. The imaging visit date served as the start to follow-up. Survival analysis was performed treating ischemic stroke/TIA as primary endpoint and death as a competing event. Participants experiencing neither event by 01.01.2025

were censored at that date.

2.1.6 Assessments of cognitive function

Nine cognitive tests were performed as part of a touchscreen questionnaire on the date of the imaging visit. Detailed description of these tests can be found elsewhere [25,26]. Standardized values (Z-Scores) were calculated for each of the test scores. Results of trail making tests and reaction time were multiplied with -1 so that higher scores correlate with better cognitive function. Then Z-Scores were averaged to four cognitive domains; executive function (Tower Rearranging Test, Trail Making Test Part B), processing speed (Reaction Time Test, Digit Symbol Substitution Test, Trail Making Test Part A), memory (Numeric Memory Test, Paired Associate Learning Test, Prospective Memory Test), and reasoning (Fluid Intelligence Test, Matrix Pattern Completion Test) as has been done in previous studies [27]. The Z-Scores of the four domains were then averaged to receive an overall score for cognitive function.

2.1.7 Statistical Analysis

All analyses were performed using R Studio with R version 4.4.0 on the UK Biobank research analysis platform. Analysis of stroke risk was performed using the survival package [28]. For assessment of ischemic stroke/TIA risk a competing risks analysis treating ischemic stroke/TIA and death as competing events was performed. According to previous recommendations from literature [29] we calculated cause specific and subdistribution hazard models, to assess the association of LAVi and LA:LV ratio with ischemic stroke/TIA risk using multivariate Cox regression. To complete the survival analysis, we performed the same regressions for the competing event, death. We employed both unadjusted models and models adjusted for the covariates described above. We tested for violation of the proportional hazard assumption by assessing Schoenfeld residuals using the cox.zph function, which is an implementation of [30]. We investigated sex differences by including an interaction term between LA:LV ratio and

sex and LAVi and sex respectively in separate models.

Linear regression models were calculated to assess the association of LAVi and LA:LV ratio, with cognitive function, both without adjustment and fully adjusting for the covariates described above. We investigated a potential nonlinear association between LAVi or LA:LV ratio and cognitive function using restricted cubic spline with three nodes using the rms package [31]. Significance of nonlinear components was assessed using partial F test for non-linear components. Finally, we investigated whether there was an interaction between sex and LAVi for the association with cognitive function.

Further, we assessed the associations of LAVi and LA:LV ratio with magnetic resonance image measured volumes of 66 cortical parcellations according to Desikan-Killiany parcellation [32] using linear regression models adjusted for age, sex and intracranial volume. We adjusted for multiple testing using the Benjamini-Hochberg procedure. The temporal pole parcellation is not available in the UK Biobank data due to its unreliable segmentation and was thus excluded. Details can be found in the Supplemental Methods. We again excluded all participants with previous stroke, AF, heart failure, reduced EF, LV dilation or missing data.

2.2 Assessing left cardiac volumes for detection of AF as cause of stroke in ischemic stroke patients from the USZ.

2.2.1 Stroke patient data

Data of all patients who had not refused consent for use of their routine data for research, treated for ischemic stroke at the USZ in the years 2023 and 2024 were retrospectively collected. We received permission from the Cantonal Ethics committee Zurich to perform this data collection (PREDICT, BASEC-ID: PB_2016_01751). For patients with multiple ischemic strokes within the two years, only information from the first ischemic stroke was included. Cardiac volumes, including left atrial volume, left ventricular end diastolic volume

and left ventricular end systolic volume as well as body surface area, were extracted from echocardiography reports, routinely performed after ischemic stroke. For the values to be included in the study, the echocardiography had to be performed after the ischemic stroke diagnosis and before the outpatient checkup at approximately three months after stroke. LAV was measured using the biplane method, at the end of systole, capturing maximum atrial volume as recommended by guidelines [33, 34]. Patients with reduced LV ejection fraction and increased LVEDVi were once again excluded. Details can be found in the supplemental methods.

Stroke etiology was identified from three-month checkup report if available or discharge report. Like in previous studies [14], stroke etiology was categorized into three subgroups: 1) AF, 2) other determined cause and 3) unknown etiology/incomplete workup. The criteria are shown in Table 1. Patients with unknown etiology or incomplete work up were excluded from the analysis. An overview can be found in Figure 1.

Prior diseases reported in Table 2, BMI, age and sex were extracted from the Swiss Stroke registry.

2.2.2 Statistical analysis

Multivariate logistic regression models for the association of LAVi and LA:LV ratio with AF being associated as stroke cause were calculated for LAVi and LA:LV ratio, both in unadjusted models and adjusting for age and sex. Then, the classification performance of LAVi and LA:LV ratio was compared. Area under the receiver operating characteristic curve (ROC-AUC) were calculated for LAVi and LA:LV ratio for classifying stroke cause as either AF or other determined stroke etiology and compared using DeLongs test [35]. Then the ideal cut off point in our sample for both parameters was calculated by maximizing the Youden index [36]. Using 10- fold cross validation, sensitivity and specificity as well as positive and negative likelihood ratios were calculated for the two parameters. We also

evaluated predictive performance in male and female patients separately.

Finally, we investigated if LA:LV ratio held complimentary information to MR proANP, a blood biomarker, which is also used to indicate atrial cardiopathy [37]. This parameter was also extracted from health records of patients if assessed during in-hospital stay of the stroke patient. We fitted a logistic regression including age, sex, LA:LV ratio and the logarithm of MR proANP levels (log(MR proANP) and assessed the performance of this model for predicting AF as stroke cause using 10-fold cross validation.

3. Results

Figure 1 shows the inclusion/exclusion flow chart for participants included into the three analyses. For the analysis of cardiac volumes and risk of ischemic stroke/TIA (analysis 1) 26'955 participants were included. For analysis of cognitive function (analysis 2), 17'133 participants were included. Although both analyses started with the same initial UK Biobank dataset, a substantial number of participants lacked complete cognitive assessments, resulting in a smaller sample size for analysis 2 compared to analysis 1. A summary of cohort characteristics is shown in Table 2. The two cohorts from the UK Biobank showed similar characteristics with both having a mean age of 64 years (SD: 7 years) and 48% male sex. Mean cardiac chamber volumes were within the range of normal (LAVi: 38 ± 10 ml/m^2, LVEDVi: Mean: 78 ± 12 ml/m^2) for both cohorts [38]. In the cohort of ischemic stroke patients (analysis 3), patients with AF as stroke etiology were older (75 ± 15 years) and more frequently female (60.5%), which aligns with previous findings [39].

Cardiac chamber volumes as measured by echocardiography in the clinical cohort were smaller compared to the UK Biobank cohort (LAVi: 38 ml/m^2 vs 32 ml/m^2, LVEDVi: 78 ml/m^2 vs 48 ml/m^2), which is consistent with the known tendency of echocardiography, to

underestimate chamber volumes compared to CMR [40].

We visually investigated the association of LAVi and LA:LV ratio with age, sex and everyday physical activity as determined by the IPAQ score in the UK Biobank cohort (Figure 2). Noticeably, LAVi showed an association with physical activity, with larger volumes being associated with higher levels of physical activity. Importantly, women showed larger mean LA:LV ratios than men, while no big sex difference was observed for LAVi. This finding is consistent with previous studies showing that LAVi is similar between sexes while men typically have larger LVEDVi. [38] These results were also confirmed using linear regression models (Table S2, S3). To account for potential sex differences, all subsequent analysis were controlled for sex and investigated for sex specific effects.

To investigate association of LA:LV ratio and LAVi with events of brain ischemia, we then conducted Cox regression for ischemic stroke/TIA, treating death as competing event. Both in unadjusted (Table S4) and fully adjusted models (Table 3) LAVi was not significantly associated with ischemic stroke. In contrast, larger LA:LV ratio was significantly associated with an increased risk of ischemic stroke/TIA in adjusted and unadjusted models. When additionally including interaction terms with sex to the adjusted models, we observed no significant interactions between sex and LAVi ($p = 0.14$) and sex and LA:LV ratio ($p = 0.83$), meaning that there is no significant evidence for sex differences for these associations. No significant associations were found between cardiac volumes and mortality (Table S5). None of the models showed significant violation of the proportional hazard's assumption. Results for subdistribution hazard models showed similar results for both ischemic stroke/TIA and mortality (Table S6, S7).

We then investigated and compared associations of LAVi and LA:LV ratio with cognitive function using multivariate linear regression models. In fully adjusted models, higher

standardized LAVi was weakly associated with poorer cognitive function [Regression coefficient: - 0.010, 95%CI (- 0.019) - (- 0.002)], while larger LA:LV ratio was more strongly associated with poorer cognitive function [Regression coefficient: - 0.024, 95% CI (- 0.032) - (- 0.015)] (Table 3). Unadjusted models showed similar results with larger LA:LV ratio being more strongly associated with poor cognitive function than LAVi (Table S4). In separate fully adjusted models, no significant interactions for sex and LAVi ($p = 0.83$) or LA:LV ratio ($p = 0.70$) were observed, indicating that there is no significant evidence that the found associations differ between sexes. We found no evidence of nonlinearity in the relationship between LAVi and LA:LV ratio using restricted cubic splines with three nodes (Figure S1).

Larger LA:LV ratio was associated with cortical atrophy especially in the temporal lobe, insula and cingulate cortex. Associations with LAVi were weaker (Figure 3, Supplemental Data). This provides a potential link between larger LA:LV and worse cognitive function. Interestingly, atrophy in temporal lobe, insula and cingulate cortex have been previously linked to AF and atrial cardiopathy [41,42], so the associations we found with LA:LV ratio could potentially represent an atrial cardiopathy related brain imaging phenotype.

Next, we examined the association of standardized LAVi and LA:LV ratio with the probability of atrial fibrillation being identified as the cause of stroke in a cohort of 289 ischemic stroke patients from the USZ. Results are shown in Table 3. Both standardized LAVi and LA:LV ratio were strongly associated with AF as the stroke cause, with the effect size of LA:LV ratio being slightly larger in adjusted modes (LA:LV ratio: Log Odds ratio: 1.7, 95% CI 1.1 – 2.3, $p < 0.001$, LAVi: Log Odds ratio: 1.4 95% CI 0.9 - 1.9, $p < 0.001$) and unadjusted models (Table S4). The LA:LV ratio showed a significantly higher ROC-AUC compared to the LAVi for identifying AF as the stroke cause (0.856 (0.803 - 0.908) vs. 0.808 (0.750 - 0.866) $p = 0.03$) (Figure 4). LA:LV ratio outperformed LAVi on all

calculated test metrics (Table 4).

A sex stratified analysis showed that LA:LV ratio showed higher ROC-AUC for identifying AF as the stroke cause than LAVi in both sexes. The ideal cut-off as calculated by the Youden Index was higher for women compared to men (Women: 0.85 95% CI 0.69 – 0.96, Men: 0.71 95% CI 0.55 – 0.86). (Table S8)

In a logistic regression model including LA:LV ratio, log(MR proANP), age and sex, both higher log(MR proANP) and higher LA:LV ratio were significantly associated with an increased likelihood of AF as stroke cause. (Table S9) The multivariate model showed an improved ROC-AUC for predicting AF as stroke cause (0.897, 95% CI 0.849 - 0.945) compared to LA:LV ratio alone although the difference was not statistically significant. ($p = 0.28$). (Figure S2).

4. Discussion

In our analyses, the LA:LV ratio consistently showed stronger associations than LAVi with clinically relevant manifestations of atrial cardiopathy. In the UK Biobank, higher LA:LV ratios were linked to greater risk of ischemic stroke/TIA and poorer cognitive function, without sex-specific differences in these associations. Further, larger LA:LV ratio was significantly associated with cortical atrophy especially in temporal lobe, insula and cingulate cortex, providing a potential link between larger LA:LV ratio and worse cognitive function. In stroke patients, the LA:LV ratio showed superior diagnostic performance for detecting AF as the stroke cause, with higher ROC-AUCs in both sexes and sex-specific optimal cut-offs.

Our findings align with our hypothesis that LA:LV ratio is more strongly associated with sequelae of atrial cardiopathy than LAVi and show its potential as a marker for atrial

cardiopathy. We hypothesize that this is because it addresses key limitations of LAVi for assessing atrial cardiopathy.

There is abundant evidence that the left atrial and the left ventricular function are interdependent [43]. For example, changes in left atrial function influence left ventricular filling pressure and vice versa [43]. The interplay of left atrium and left ventricle is further influenced by myocardial compliance and upstream hemodynamic stress. [44]. This complex interplay of left atrium and ventricle is not captured by measuring LAVi alone. In contrast, while no single marker could ever fully characterize these interactions, the LA:LV ratio is a straightforward way of assessing the left atrium, while incorporating information from the left ventricle.

We hypothesize that, as it allows joint assessment the left atrium and ventricle, the LA:LV ratio can better distinguish between balanced and unbalanced cardiac remodeling. While there is little literature directly comparing the effects of balanced and unbalanced atrial remodeling on the risk of cardiovascular events, there is some evidence comparing the effects of left atrial enlargement (LAE) in physically active and inactive people. Participants with LAE who were physically active, had a significantly lower risk of AF compared to inactive participants with LAE. [45] Further, physical activity has been associated with reduced risk of AF and stroke [46,47]. Hence, we hypothesize that an increased LAVi with unchanged or decreased LVEDVi best represents an atrial cardiopathy phenotype, which would be associated with increased risk of stroke, worse cognitive function and increased probability of AF as stroke cause, while increased LAVi coupled with increased LVEDVi would be more representative of physiological changes, e.g. induced by increased physical activity, which would be less associated with adverse cardiovascular events. However more, especially longitudinal studies are needed to further investigate this hypothesis.

The LA:LV ratio has the potential to be incorporated into clinical practice for several reasons. Firstly, we show that it significantly outperforms LAVi, an established marker of atrial cardiopathy, in an important clinical setting: identifying stroke patients with atrial fibrillation as underlying cause of stroke. This is essential, as ischemic stroke patients with atrial fibrillation require anticoagulation rather than the standard prophylactic treatment of platelet aggregation inhibitors to be adequately protected from stroke recurrence. [48] LA:LV ratio could be used to select ischemic stroke patients for long term rhythm monitoring to detect underlying AF. Increased LA:LV ratio might even become a sufficient justification for prescribing anticoagulation in ischemic stroke patients, especially in patients, where no other convincing stroke etiology is found, as atrial cardiopathy can lead to cardioembolic stroke even in the absence of AF [7]. Secondly, LA:LV ratio can be easily calculated from LAVi and LVEDVi, which are both routinely measured in clinical practice according to established protocols. Finally, the superiority of LA:LV ratio can be mechanistically explained as it addresses key limitations of LAVi for diagnosis of atrial cardiopathy. Hence, this study should inspire prospective multicenter trials to facilitate the establishment of LA:LV ratio in clinical practice, especially as part of diagnostic work-up of ischemic stroke.

4.1 Strengths and Limitations

Use of UK Biobank data is a strength of this study. Firstly, it is a very large dataset, and allowed assessing left atrial and left ventricular volumes using magnetic resonance imaging, which is a reliable way of quantifying cardiac volumes [34, 41]. In addition, in the UK Biobank, a wide array of cognitive tests was performed, covering different facets of cognition with adequate reliability [26].

Due to the wide array of exposures assessed in the UK Biobank study, we were able to adjust for many potential confounders. Finally, due to the large sample size, we were

able to screen for interactions and non-linearity of associations.

However, due to the observational nature of this study, the possibility of residual confounding cannot be ruled out. By adjusting for a wide array of potential confounders we aimed to minimize this. Another limitation is that due to the large sample size, statistically significant but not clinically relevant associations might be detected. It is also important to keep in mind that the UK Biobank is a healthy cohort with a slight "healthy volunteer" selection bias compared to the general population [49]. This could reduce generalizability of our findings to other populations. Further, both the UK Biobank and the USZ cohort of ischemic stroke patients are predominantly White, limiting generalizability to individuals from other racial and ethnic backgrounds. Another limitation of our study is that we deliberately excluded subjects with heart failure, reduced EF and LV dilation as interaction between LAVi and LVEDVI are different in these patients. These subjects should be studied in dedicated cohorts. Finally, although longitudinal studies have been conducted on effects of exercise on heart volumes [15], supporting our mechanistic hypothesis, establishing causality is not possible with an observational, cross-sectional approach.

4.2 Conclusions

We show that LA:LV ratio has the potential to improve diagnosis of atrial cardiopathy as it showed stronger associations with clinically relevant manifestations of atrial cardiopathy than LAVi, which is the current clinical standard. Prospective, multicenter studies are needed to further validate our findings and establish sex specific reference values to facilitate the use of LA:LV ratio in clinical practice.

5 Acknowledgements

This research has been conducted using the UK Biobank Resource under application number 467527. UK Biobank will make the data available to all bona fide researchers

for all types of health-related research that is in the public interest. For more details on the access procedure, see the UK Biobank website: http://www.ukbiobank.ac.uk/register-apply/. This work uses data provided by patients and collected by the NHS as part of their care and support. The clinical data analyzed in this study will be made available upon reasonable request. The Graphical Abstract was created in BioRender. https://BioRender.com/qmqdggl

6 Sources of Funding

This work was supported by the UK Biobank Platform Credits Programme for covering computational costs, and the Swiss National Science Foundation (SNSF 310030_200703).

7 Disclosures

None

8 Supplemental Material

Detailed Methods

Tables S1-S9

Figures S1-S2

Supplemental Data

9 References

1. Goette A, Lendeckel U. Atrial Cardiomyopathy: Pathophysiology and Clinical Consequences. Cells. 2021;10(10).
2. Edwards JD, Healey JS, Fang J, Yip K, Gladstone DJ. Atrial Cardiopathy in the Absence of Atrial Fibrillation Increases Risk of Ischemic Stroke, Incident Atrial Fibrillation, and Mortality and Improves Stroke Risk Prediction. J Am Heart Assoc. 2020;9(11):e013227.
3. Myers SJ, Jiménez-Ruiz A, Sposato LA, Whitehead SN. Atrial cardiopathy and cognitive impairment. Front Aging Neurosci. 22. July 2022
4. Zhang JC, Bhat A. Atrial Cardiopathy: Redefining Stroke Risk Beyond Atrial Fibrillation. The American Journal of Cardiology. August 2023;201:177–84.
5. Johansen MC, Wang W, Zhang M, Knopman DS, Ndumele C, Mosley TH, et al. Risk of Dementia Associated With Atrial Cardiopathy: The ARIC Study. J Am Heart Assoc. 2022;11(16):e025646.
6. Wang W, Zhang MJ, Inciardi RM, Norby FL, Johansen MC, Parikh R, et al. Association of Echocardiographic Measures of Left Atrial Function and Size With Incident Dementia. Jama. 2022;327(12):1138-48.
7. Healey JS, Gladstone DJ, Swaminathan B, Eckstein J, Mundl H, Epstein AE, et al. Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial. JAMA Neurol. 2019;76(7):764-73.
8. Kamel H, Okin PM, Longstreth WT, Jr., Elkind MS, Soliman EZ. Atrial cardiopathy: a broadened concept of left atrial thromboembolism beyond atrial fibrillation. Future Cardiol. 2015;11(3):323-31..
9. Overvad TF, Nielsen PB, Larsen TB, Søgaard P. Left atrial size and risk of stroke in patients in sinus rhythm. A systematic review. Thromb Haemost. 2016;116(2):206-19..
10. Di Tullio MR, Sacco RL, Sciacca RR, Homma S. Left atrial size and the risk of ischemic

stroke in an ethnically mixed population. Stroke. 1999;30(10):2019-24.

11. Larsen BS, Olsen FJ, Andersen DM, Madsen CV, Møgelvang R, Jensen GB, et al. Left Atrial Volumes and Function, and Long-Term Incidence of Ischemic Stroke in the General Population. J Am Heart Assoc. 2022;11(18):e027031.
12. Alosco ML, Gunstad J, Jerskey BA, Clark US, Hassenstab JJ, Xu X, et al. Left atrial size is independently associated with cognitive function. Int J Neurosci. 2013;123(8):544-52.
13. Gonzalez Casanova I, Alonso-Gómez Á M, Romaguera D, Toledo E, Fortuny E, López L, et al. Association of Left Atrial Structure and Function With Cognitive Function in Adults With Metabolic Syndrome. Am J Cardiol. 2022;183:122-8.
14. Jordan K, Yaghi S, Poppas A, Chang AD, Mac Grory B, Cutting S, et al. Left Atrial Volume Index Is Associated With Cardioembolic Stroke and Atrial Fibrillation Detection After Embolic Stroke of Undetermined Source. Stroke. 2019;50(8):1997-2001.
15. McNamara DA, Aiad N, Howden E, Hieda M, Link MS, Palmer D, et al. Left Atrial Electromechanical Remodeling Following 2 Years of High-Intensity Exercise Training in Sedentary Middle-Aged Adults. Circulation. 2019;139(12):1507-16.
16. Letnes JM, Nes B, Vaardal-Lunde K, Slette MB, Mølmen-Hansen HE, Aspenes ST, et al. Left Atrial Volume, Cardiorespiratory Fitness, and Diastolic Function in Healthy Individuals: The HUNT Study, Norway. J Am Heart Assoc. 2020;9(3):e014682..
17. Spencer LW, D'Ambrosio P, Ohanian M, Rowe SJ, Janssens K, Claessen G, et al. Atrial cardiomyopathy in endurance athletes. npj Cardiovasc Health. November 2024;1(1):1–9.
18. Sabo S, Dalen H, Nyberg J, Grenne BL, Jakobsen EO, Nes BM, et al. Left atrial to ventricular volume ratio and relation to fitness, cardiovascular risk factors, and diastolic function in healthy individuals: the HUNT Study. Eur Heart J Imaging Methods Pract. 2024;2(1):qyae028.
19. UK Biobank: Protocol for a Large-Scale Prospective Epidemiological Resource, 2007.

https:// www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UK-Biobank-Protocol. pdf (06 February 2025, date last accessed)

20. Petersen SE, Matthews PM, Francis JM, Robson MD, Zemrak F, Boubertakh R, et al. UK Biobank's cardiovascular magnetic resonance protocol. J Cardiovasc Magn Reson. 2016;18:8.
21. Bai W, Suzuki H, Huang J, Francis C, Wang S, Tarroni G, et al. A population-based phenome-wide association study of cardiac and aortic structure and function. Nat Med. 2020;26(10):1654-62.
22. Hundley WG, Bluemke DA, Bogaert J, Flamm SD, Fontana M, Friedrich MG, et al. Society for Cardiovascular Magnetic Resonance (SCMR) guidelines for reporting cardiovascular magnetic resonance examinations. J Cardiovasc Magn Reson. 2022;24(1):29.
23. Laubrock K, von Loesch T, Steinmetz M, Lotz J, Frahm J, Uecker M, et al. Imaging of arrhythmia: Real-time cardiac magnetic resonance imaging in atrial fibrillation. Eur J Radiol Open. 2022;9:100404.
24. Takeuchi M, Kitano T, Nabeshima Y, Otsuji Y, Otani K. Left ventricular and left atrial volume ratio assessed by three-dimensional echocardiography: Novel indices for evaluating age-related change in left heart chamber size. Physiol Rep. 2019;7(23):e14300.
25. Fawns-Ritchie C, Deary IJ. Reliability and validity of the UK Biobank cognitive tests. PLoS One. 2020;15(4):e0231627.
26. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. March 2015;12(3):e1001779.1.
27. Petersen M, Chevalier C, Naegele FL, Ingwersen T, Omidvarnia A, Hoffstaedter F, et al. Mapping the interplay of atrial fibrillation, brain structure, and cognitive dysfunction. Alzheimers Dement. 2024;20(7):4512-26.

28. Therneau T (2024). A Package for Survival Analysis in R. R package version 3.8-3
29. Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol. July 2009;170(2):244–56.
30. P. Grambsch and T. Therneau (1994), Proportional hazards tests and diagnostics based on weighted residuals. *Biometrika,* **81**, 515-26
31. Lenth RV. Response-Surface Methods in R, Using rsm. Journal of Statistical Software. 2010;32:1–17.1
32. Desikan RS, Ségonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31(3):968-80.
33. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.e14.
34. Nagueh SF, Sanborn DY, Oh JK, Anderson B, Billick K, Derumeaux G, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography and for Heart Failure With Preserved Ejection Fraction Diagnosis: An Update From the American Society of Echocardiography. J Am Soc Echocardiogr. 2025;38(7):537-69.
35. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837-45.
36. Schisterman EF, Faraggi D, Reiser B, Hu J. Youden Index and the optimal threshold for markers with mass at zero. Stat Med. 2008;27(2):297-315.
37. Schweizer J, Arnold M, König IR, Bicvic A, Westphal LP, Schütz V, et al.

Measurement of Midregional Pro-Atrial Natriuretic Peptide to Discover Atrial Fibrillation in Patients With Ischemic Stroke. J Am Coll Cardiol. 2022;79(14):1369-81.

38. Kawel-Boehm N, Hetzel SJ, Ambale-Venkatesh B, Captur G, Francois CJ, Jerosch-Herold M, et al. Reference ranges ("normal values") for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update. J Cardiovasc Magn Reson. 2020;22(1):87.
39. Arboix A, Massons J, García-Eroles L, Targa C, Parra O, Oliveres M. Trends in clinical features and early outcome in patients with acute cardioembolic stroke subtype over a 19-year period. Neurol India. 2012;60(3):288-93.
40. Zhao D, Quill GM, Gilbert K, Wang VY, Houle HC, Legget ME, et al. Systematic Comparison of Left Ventricular Geometry Between 3D-Echocardiography and Cardiac Magnetic Resonance Imaging. Front Cardiovasc Med. 2021;8:728205.
41. Liao GZ, He CH, Li XQ, Xiong Y, Huang LY, Xin AR, et al. Exploring the heart-brain and brain-heart axes: Insights from a bidirectional Mendelian randomization study on brain cortical structure and cardiovascular disease. Neurobiol Dis. 2024 Oct 1;200:106636. PubMed PMID: 39142612. Epub 20240812. eng.
42. Huang LJ, Chen JS, Song YZ, Chang P. Atrial fibrillation and cognitive impairment: mechanisms, influencing factors, and prospects. Front Cardiovasc Med. 2025;12:1527802. doi: 10.3389/fcvm.2025.1527802
43. Ferkh A, Clark A, Thomas L. Left atrial phasic function: physiology, clinical assessment and prognostic value. Heart. 2023;109:1661-1669. doi: 10.1136/heartjnl-2022-321609.
44. Pergola V, D'Andrea A, Galzerano D, Mantovani F, Rizzo M, Giannuario GD, et al. Unveiling the Hidden Chamber: Exploring the Importance of Left Atrial Function and Filling Pressure in Cardiovascular Health. J Cardiovasc Echogr. 2023;33(3):117-24.
45. Heitmann KA, Løchen ML, Stylidis M, Hopstock LA, Schirmer H, Morseth B. Associations between physical activity, left atrial size and incident atrial fibrillation: the

Tromsø Study 1994-2016. Open Heart. 2022;9(1).

46. Elliott AD, Linz D, Mishima R, Kadhim K, Gallagher C, Middeldorp ME, et al. Association between physical activity and risk of incident arrhythmias in 402 406 individuals: evidence from the UK Biobank cohort. Eur Heart J. 2020;41(15):1479-86.
47. Jin MN, Yang PS, Song C, Yu HT, Kim TH, Uhm JS, et al. Physical Activity and Risk of Atrial Fibrillation: A Nationwide Cohort Study in General Population. Sci Rep. 2019;9(1):13270.
48. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021;52(7):e364-e467.
49. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. Am J Epidemiol. 2017;186(9):1026-3

Supplementary References

50. Huang YT, Wei T, Huang YL, Wu YP, Chan KA. Validation of diagnosis codes in healthcare databases in Taiwan, a literature review. Pharmacoepidemiol Drug Saf. 2023;32(7):795-811.

10 Tables

Classification	Criteria
Atrial Fibrillation or Flutter	• Atrial fibrillation or flutter detected in 12 channel ECG during workup or documented in medical history prior to stroke • No other plausible etiology for ischemic stroke identified
Other determined etiology	• Other cause of ischemic stroke identified (e.g. large vessel atherosclerosis, small vessel occlusion, vessel dissection etc.) • A minimum of 48h of rhythm monitoring performed, without detection of atrial fibrillation or flutter. • No atrial fibrillation or flutter documented in the medical history
Unknown etiology or incomplete workup	• Criteria for neither of the groups above met.

Table 1. Criteria for classifying stroke etiology.

	UKBB: Risk of Ischemic stroke/TIA	UKBB: Cognitive function	USZ Stroke patients: Stroke Etiology	
			Non-AF	AF
n	26’955	17’133	213	76
Age (mean (SD))	63.52 (7.48)	63.81 (7.33)	60.24 (17.08)	74.87 (15.09)
Sex = Male (%)	12891 (47.8)	8280 (48.3)	135 (63.4)	30 (39.5)
LAVi [ml/m^2]	38.12 (10.21)	38.13 (10.29)	28.26 (7.99)	44.41 (17.83)
LA:LV ratio (mean (SD))	0.49 (0.12)	0.49 (0.12)	0.59 (0.19)	1.07 (0.49)
LVEDVi (mean (SD)) [ml/m^2]	77.84 (11.68)	77.78 (11.66)	49.62 (10.32)	43.31 (8.99)
Hypertension (%)	7358 (27.3)	4565 (26.6)	118 (55.4)	59 (77.6)
Diabetes (%)	1258 (4.7)	771 (4.5)	46 (21.6)	21 (27.6)
Vascular disease (%)	911 (3.4)	585 (3.4)	NA	NA
Dyslipidemia (%)	5475 (20.3)	3467 (20.2)	88 (41.3)	31 (40.8)
BMI (mean (SD)) [kg/m^2]	26.38 (4.30)	26.36 (4.34)	25.21 (4.11)	26.47 (4.34)
Physical Activity (%)			NA	NA
- high	12345 (45.8)	8043 (46.9)		
- moderate	3100 (11.5)	1843 (10.8)		
- low	11510 (42.7)	7247 (42.3)		
Smoking (%) [†]				
- never	17053 (63.3)	10989 (64.1)	141 (66.2)	66 (86.8)
- current	931 (3.5)	523 (3.1)	70 (32.9)	10 (13.2)
- previous	8971 (33.3)	5621 (32.8)		
Alcohol (%)			NA	NA
- Never	1658 (6.2)	1007 (5.9)		
- (almost) daily	4523 (16.8)	2814 (16.4)		
- 3-4 x a week	7209 (26.7)	4606 (26.9)		
- 1-2 x a week	3078 (11.4)	1975 (11.5)		
- 1-3 x times a month	2666 (9.9)	1636 (9.5)		
- Special occasions only	7821 (29.0)	5095 (29.7)		
Townsend deprivation index (mean (SD))	-1.95 (2.68)	-1.95 (2.69)	NA	NA
University degree (%)		9196 (53.7)	NA	NA

Table 2. **Baseline Characteristics of the studied cohorts.** UKBB: UK Biobank, AF: Atrial fibrillation/flutter, LAVi: left atrial volume indexed to body surface area, LVEDVi: left ventricular end-diastolic volume indexed to body surface area, LA:LV ratio: left atrial to ventricular volume ratio. SD: standard deviation

“UKBB: Ischemic stroke” is a subpopulation of the UK Biobank cohort used for analysis of association of ischemic stroke risk and cardiac volumes. “UKBB: Cognitive function” is a subpopulation of the UK Biobank used do assess association of cardiac volumes and cognitive function. “USZ stroke patients: Stroke etiology” is a cohort of ischemic stroke patients from the USZ.

For ischemic stroke patients, smoking status was only available classified as current/previous or never. For two patients smoking status was not available.

Ischemic stroke/TIA			
	Hazard ratio	95% CI	P -value
LAVi	1.11	0.97 - 1.26	0.14
LA:LV ratio	1.15	1.01 - 1.30	**0.04**
Cognitive function			
	Coefficient	95% CI	P -value
LAVi	-0.010	(- 0.019) - (- 0.002)	**0.02**
LA:LV ratio	-0.024	(- 0.032) - (- 0.015)	**< 0.001**
Atrial fibrillation as ischemic stroke cause			
	Log Odds ratio	95% CI	P-value
LAVi	1.4	0.9 - 1.9	**< 0.001**
LA:LV ratio	1.7	1.2 - 2.3	**< 0.001**

Table 3. Associations of standardized left atrial volume index and standardized left atrial to left ventricular volume ratio with sequelae of atrial cardiopathy. LAVi: left atrial volume index, LA:LV ratio: left atrial to ventricular volume ratio

Hazard ratios from cause specific hazard models for ischemic stroke with death as competing event. HR > 1 indicate increased hazard rate of ischemic stroke/TIA. For LAVi and LA:LV ratio two separate models were calculated each adjusted for the described covariates. 249 participants had an ischemic stroke/TIA as an endpoint (TIA: 88, ischemic stroke: 161), 606 deaths. Median time under observation was 6.8 years.

Linear regression coefficients for cognitive function as independent variable. Coefficients > 0 indicate association of larger volumes with better cognitive function. For LAVi and LA:LV ratio two separate models were calculated each adjusted for the described covariates.

Log odds ratio for AF as stroke cause as independent variable in multivariate logistic regression. Coefficients > 0 indicate association of larger volumes with AF as stoke cause. For LAVi and LA:LV ratio two separate models were calculated each adjusted for age and sex. 289 ischemic stroke patients included, 76 with atrial fibrillation as stroke cause.

	LA:LV ratio	LAVi
Optimal cut off point	0.81 (0.68 - 0.87)	35 ml/m^2 (34 -36)
Sensitivity	0.684 (0.573 -0.778)	0.658 (0.546 - 0.755)
Specificity	0.850 (0.796 - 0.892)	0.808 (0.749 - 0.855)
LR +	4.6 (3.3 - 6.7)	3.4 (2.5 - 4.8)
LR -	0.37 (0.25 - 0.50)	0.42 (0.29 - 0.56)

Table 4. Test metrics of LA:LV ratio and LAVi for detecting atrial fibrillation as stroke cause with 95% CI. LA:LV ratio: left atrial to ventricular volume ratio, LAVi: left atrial volume indexed to body surface area, LR +: positive likelihood ratio, LR –: negative likelihood ratio

Optimal cut o□ calculated by maximizing Youden Index 95% CI calculated using 1000 bootstrap samples.

Test metrics calculated using 10-fold cross validation. 95% CI are Wilson CI.

11 Figures



Figure 1. Inclusion Flow chart. LA: left atrium, LV: left ventricle, EF: Ejection fraction



Figure 2. (A) Association of Age, Sex and Activity with left atrial volume indexed to body surface area. (B) Association of Age, Sex and Activity with left atrial to ventricular volume ratio. Results from UK Biobank cohort used for ischemic stroke/TIA analysis. Blue lines show linear regression lines. For LAVi and LA:LV ratio outliers more than three standard deviations from the mean are not shown. Boxplots show mean (point) and median (line) values with interquartile range. Values outside two standard deviations from the mean are not shown. LAVi: left atrial volume indexed to body surface area, LA to LV ratio: left atrial to ventricular volume ratio, L: low, M: medium, H: high.



Figure 3. (A) Associations of LAVi with cortical volumes according to Desikan-Killiany parcellation. (B) Associations of LA:LV ratio with cortical volumes according to Desikan-Killiany parcellation. Colors show significant regression coefficients for association of standardized cortical volume with standardized LAVi/LA:LV ratio, adjusted for age, sex and intracranial volume. Red regions show atrophy associated with larger LAVi/LA:LV ratio. Parcellation of the temporal pole (grey) was not performed in the UK Biobank data due to unreliable results. Analysis included 28’954 participants with available heart and brain imaging. Plot created using python package pySimpleBrainPlot. LAVi: left atrial volume indexed to body surface area, LA to LV ratio: left atrial to ventricular volume ratio.



Figure 4. Receiver operating characteristic curves for LAVi and LA:LV ratio for detecting atrial fibrillation as stroke cause. Area under the curve with 95 % CI is shown in the bottom right. Confidence intervals were calculated based on 1000 bootstrap samples. P value calculated with DeLong's test. LAVi: Left atrial volume indexed to body surface area. LA:LV ratio: Left atrial to ventricular volume ratio, ROC: Receiver operating characteristic, AUC: Area under the Curve.